Skip to main content
PMC home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1997 Jan;4(1):107–111. doi: 10.1128/cdli.4.1.107-111.1997

Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques.

M Ohlin 1, M Silvestri 1, V A Sundqvist 1, C A Borrebaeck 1
PMCID: PMC170486  PMID: 9008292

Abstract

An electrochemiluminescence technique was used to develop versatile and sensitive assay strategies for determination of seroreactivities against biologically important cytomegalovirus neutralization epitopes expressed on glycoprotein B. Indirect binding assays showed wide linear assay ranges and revealed that serum samples diluted in parallel with a monoclonal antibody-based standard, simplifying quantitative analytical assessments.

Full Text

The Full Text of this article is available as a PDF (185.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler S. P. Current prospects for immunization against cytomegaloviral disease. Infect Agents Dis. 1996 Jan;5(1):29–35. [PubMed] [Google Scholar]
  2. Britt W. J., Vugler L., Butfiloski E. J., Stephens E. B. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol. 1990 Mar;64(3):1079–1085. doi: 10.1128/jvi.64.3.1079-1085.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chou S., Marousek G. I. Homology of the envelope glycoprotein B of human herpesvirus-6 and cytomegalovirus. Virology. 1992 Nov;191(1):523–528. doi: 10.1016/0042-6822(92)90224-d. [DOI] [PubMed] [Google Scholar]
  4. Goade D. E., Bell R., Yamada T., Mertz G. J., Jenison S. Locations of herpes simplex virus type 2 glycoprotein B epitopes recognized by human serum immunoglobulin G antibodies. J Virol. 1996 May;70(5):2950–2956. doi: 10.1128/jvi.70.5.2950-2956.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gönczöl E., Berensci K., Pincus S., Endresz V., Méric C., Paoletti E., Plotkin S. A. Preclinical evaluation of an ALVAC (canarypox)--human cytomegalovirus glycoprotein B vaccine candidate. Vaccine. 1995 Aug;13(12):1080–1085. doi: 10.1016/0264-410x(95)00048-6. [DOI] [PubMed] [Google Scholar]
  6. Kniess N., Mach M., Fay J., Britt W. J. Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus. J Virol. 1991 Jan;65(1):138–146. doi: 10.1128/jvi.65.1.138-146.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kropff B., Landini M. P., Mach M. An ELISA using recombinant proteins for the detection of neutralizing antibodies against human cytomegalovirus. J Med Virol. 1993 Mar;39(3):187–195. doi: 10.1002/jmv.1890390303. [DOI] [PubMed] [Google Scholar]
  8. Li S. J., Cronan J. E., Jr The gene encoding the biotin carboxylase subunit of Escherichia coli acetyl-CoA carboxylase. J Biol Chem. 1992 Jan 15;267(2):855–863. [PubMed] [Google Scholar]
  9. Matsuzawa K., Koyama T., Sugawara S., Ikegawa S., Asano S., Sasaki S., Tomiyama T., Kasahara Y., Okamiya Y., Inoue K. The preclinical safety evaluation of human monoclonal antibody against cytomegalovirus. Fundam Appl Toxicol. 1992 Jul;19(1):26–32. doi: 10.1016/0272-0590(92)90024-c. [DOI] [PubMed] [Google Scholar]
  10. Meyer H., Masuho Y., Mach M. The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. J Gen Virol. 1990 Oct;71(Pt 10):2443–2450. doi: 10.1099/0022-1317-71-10-2443. [DOI] [PubMed] [Google Scholar]
  11. Meyer H., Sundqvist V. A., Pereira L., Mach M. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J Gen Virol. 1992 Sep;73(Pt 9):2375–2383. doi: 10.1099/0022-1317-73-9-2375. [DOI] [PubMed] [Google Scholar]
  12. Ohlin M., Borrebaeck C. A. Low affinity, antibody binding of an Escherichia coli-derived component. FEMS Immunol Med Microbiol. 1996 Feb;13(2):161–168. doi: 10.1016/0928-8244(95)00122-0. [DOI] [PubMed] [Google Scholar]
  13. Ohlin M., Owman H., Mach M., Borrebaeck C. A. Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Mol Immunol. 1996 Jan;33(1):47–56. doi: 10.1016/0161-5890(95)00123-9. [DOI] [PubMed] [Google Scholar]
  14. Ohlin M., Sundqvist V. A., Gilljam G., Rudén U., Gombert F. O., Wahren B., Borrebaeck C. A. Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus. Clin Exp Immunol. 1991 Jun;84(3):508–514. [PMC free article] [PubMed] [Google Scholar]
  15. Ohlin M., Sundqvist V. A., Mach M., Wahren B., Borrebaeck C. A. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies. J Virol. 1993 Feb;67(2):703–710. doi: 10.1128/jvi.67.2.703-710.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Plotkin S. A. Vaccines for varicella-zoster virus and cytomegalovirus: recent progress. Science. 1994 Sep 2;265(5177):1383–1385. doi: 10.1126/science.8073277. [DOI] [PubMed] [Google Scholar]
  17. Riddell S. R., Watanabe K. S., Goodrich J. M., Li C. R., Agha M. E., Greenberg P. D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992 Jul 10;257(5067):238–241. doi: 10.1126/science.1352912. [DOI] [PubMed] [Google Scholar]
  18. Schoppel K., Hassfurther E., Britt W., Ohlin M., Borrebaeck C. A., Mach M. Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures. Virology. 1996 Feb 1;216(1):133–145. doi: 10.1006/viro.1996.0040. [DOI] [PubMed] [Google Scholar]
  19. Spaete R. R., Gehrz R. C., Landini M. P. Human cytomegalovirus structural proteins. J Gen Virol. 1994 Dec;75(Pt 12):3287–3308. doi: 10.1099/0022-1317-75-12-3287. [DOI] [PubMed] [Google Scholar]
  20. Sundqvist V. A., Wahren B. An interchangeable ELISA for cytomegalovirus antigen and antibody. J Virol Methods. 1981 Apr;2(5):301–312. doi: 10.1016/0166-0934(81)90029-x. [DOI] [PubMed] [Google Scholar]
  21. Sällberg M., Rudén U., Magnius L. O., Norrby E., Wahren B. Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett. 1991 Sep;30(1):59–68. doi: 10.1016/0165-2478(91)90090-w. [DOI] [PubMed] [Google Scholar]
  22. Utz U., Britt W., Vugler L., Mach M. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus. J Virol. 1989 May;63(5):1995–2001. doi: 10.1128/jvi.63.5.1995-2001.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Yang H., Leland J. K., Yost D., Massey R. J. Electrochemiluminescence: a new diagnostic and research tool. ECL detection technology promises scientists new "yardsticks" for quantification. Biotechnology (N Y) 1994 Feb;12(2):193–194. doi: 10.1038/nbt0294-193. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES